Orders for an irritable bowel syndrome blood test rose 120% in September, reaching 22.
Biomerica (BMRA) reported a 120% increase in Medicare-related orders for its inFoods® IBS test in September 2026. The company processed all valid Medicare claims at a $300 rate. Operating expenses decreased 14% YoY, while OTC sales rose 81% QoQ. Cash reserves doubled to $2.7M. Net sales were $1.3M with an 8% gross margin, resulting in an operating loss of $1.2M.
How this was made
The 30-second read
Why it matters
The earnings release underscores a cash‑tight position but shows growing cash reserves and Medicare test order growth, which may be viewed positively if the trend continues.
Market read
Micro‑cap biotech earnings with modest revenue and a loss; likely short‑term downside but long‑term upside if Medicare adoption accelerates.
What to watch
Potential upside from upcoming CDM contracts and international hp+detect™ reorders not reflected in the current quarter.
Background
Biomerica is a biomedical technology company focused on point‑of‑care diagnostics, recently expanding its inFoods® IBS test and CDM services.
Ticker impact
Biomerica (NASDAQ: BMRA) released its Q1 fiscal 2027 results, reporting $1.3 M revenue, 8% gross margin, $1.3 M operating expenses and a $1.2 M operating loss.
likely downward pressure as the market prices in the operating loss and low gross margin
The press release shows revenue below prior year, a sharp drop in gross margin and an operating loss, which typically trigger sell‑offs for micro‑cap stocks.
Market effects
Highlights challenges for the diagnostic‑testing sector, especially for companies relying on Medicare reimbursement growth.
Limited to U.S. biotech micro‑caps; no broader regional effect.
Minimal global impact beyond niche diagnostic market.
Counterpoint
If the Medicare reimbursement pipeline accelerates faster than indicated, the stock could rebound on future revenue visibility.
Key entities
- CompanyBiomerica, Inc.
NASDAQ‑listed developer of diagnostic tests, ticker BMRA.
